Enveda 融资 3.11 亿美元，推进 AI 天然药物临床试验
原标题：Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
AI 摘要
生物科技初创公司 Enveda 完成 3.11 亿美元 E 轮融资，估值达 20 亿美元，由 Catalio Capital Management 领投，Iconiq 等参投，估值较 12 个月前翻倍。Enveda 利用 AI 从植物和微生物中发现新药，由 Recursion Pharmaceuticals 早期员工 Viswa Colluru 于 2019 年创立。该公司正将多款 AI 发现的候选药物推进人体临床试验，包括针对严重皮肤病的药物和帮助停用 GLP-1 后维持减重的药物。
正文节选
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmac